Table 3.
Percentage of the analysed cases with or without intratumor heterogeneity (ITH, and non-ITH, respectively) and without or with MYCN amplification (non-MNA and MNA, respectively) that showed typical segmental chromosomal aberrations (SCAs), the most frequently found atypical SCAs, and other genomic aberrations as focal SCAs in TERT and ATRX genes, number of cases with presence of alternative lengthening of telomeres (ALT positive), and presence of mutations (mut) or amplification (amp) in ALK gene.
| Cases | Typical SCAs | Atypical SCAs | Other Aberrations | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1p− | +1q | +2p | 3p− | 4p− | 11p− | +17q | +6p | 6q− | +7q | 9p− | +12q | 14q− | 19p− | 21q− | TERT | ATRX | ALT | ALK | |
| ITH non-MNA | 57% | 29% | 64% | 64% | 43% | 93% | 100% | 28% | 21% | 64% | 21% | 57% | 21% | 21% | 21% | 21% | 21% | 2 positive | 1 mut, 0 amp |
| non-ITH non-MNA | 39% | 11% | 28% | 50% | 17% | 89% | 89% | 22% | 11% | 33% | 0% | 22% | 27% | 0% | 0% | 22% | 11% | 3 positive | 1 mut, 0 amp |
| ITH MNA | 87% | 38% | 25% | 13% | 0% | 25% | 75% | 0% | 25% | 0% | 0% | 13% | 38% | 0% | 0% | 0% | 0% | - | 0 mut, 0 amp |
| non-ITH MNA | 83% | 8% | 50% | 17% | 8% | 17% | 58% | 8% | 8% | 16% | 16% | 0% | 0% | 0% | 0% | 0% | 0% | - | 1 mut, 2 amp |